Alkermes, Inc. company was founded in 1987 and is headquartered in Cambridge, Massachusetts. Alkermes, Inc., an integrated biotechnology company, offers extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes. It primarily develops, manufactures, and commercializes VIVITROL, an extended-release Medisorb formulation of naltrexone for the treatment of alcohol dependence, as well as for the treatment of opioid dependence. The company also manufactures RISPERDAL CONSTA, a formulation of risperidone for the treatment of schizophrenia and bipolar disorder. In addition, it is developing Exenatide once weekly for the treatment of type 2 diabetes; ALKS 33, an opioid modulator, which completed phase I randomized, double-blind, and placebo-controlled study for the treatment of addiction, pain, and other nervous system disorders; ALKS 29, an oral combination therapy for the treatment of alcohol dependence; ALKS 27, an inhaled trospium product that is in a phase IIa study for the treatment of chronic obstructive pulmonary disease; and ALKS 36, a co-formulation of an opioid analgesic and RDC-1036 for the treatment of pain. Alkermes, Inc. has collaborative arrangements with Janssen Pharmaceutica, Inc.; Cilag GmbH International; Amylin Pharmaceuticals, Inc.; and Rensselaer Polytechnic Institute.

Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts. Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology.

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn®, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATryn® is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.

Fertile minds at Merck Serono help people around the world combat infertility. One of the world's top biotechs, Merck Serono focuses on recombinant genetic engineering to develop drugs. The firm also manufactures and markets therapies for neurological, dermatological, metabolic, oncology, cardiovascular, and growth disorders. It is a leader in reproductive health, with flagship drug Gonal-F at the head of its infertility product line. Other key products include beta interferon drug Rebif for the treatment of multiple sclerosis (MS) and colorectal and head/neck cancer treatment Erbitux. The company is a subsidiary of German drugmaker Merck KGaA.

Light Sciences Oncology, Inc. company is in the business of developing its proprietary Light Infusion Therapy (Litx). Litx is a novel treatment for solid tumors, in which a flexible light-emitting diode (LED) is inserted into a tumor, followed by an injection of Aptocine (talaporfin sodium), a light-activated drug. Once the LED activates Aptocine, molecular oxygen is converted into singlet oxygen, killing tissue within the LED's scope and shutting down the blood supply to the area. The treatment is designed for use on cancers including liver and prostate cancers and glioma (brain tumors).

BioMS Medical Corp. was founded in 1998 and is headquartered in Edmonton, Canada. BioMS Medical Corp., a development stage biotechnology company, through its subsidiaries, engages in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS) in Canada. Its lead product under development includes Dirucotide for the treatment of multiple sclerosis, which is being evaluated in two pivotal Phase III clinical trials for secondary progressive MS patients; and MAESTRO-01, a pivotal phase II/III trial in Canada and western Europe. The company also develops Maestro-02, an open-label follow-on study to the Maestro-01 pivotal phase II/III clinical trial of Dirucotide, which targets secondary progressive multiple sclerosis (SPMS), as well as MAESTRO-03 trial, a pivotal Phase III product to evaluate the safety and efficacy of Dirucotide in patients with SPMS in the United States. BioMS Medical Corp. has a licensing and development agreement with Eli Lilly and Company. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in July 2001.

Noven Pharmaceuticals, Inc. company develops drugs using its transdermal drug delivery system, which administers medication through a patch attached to the skin. Noven's patches include such female hormone replacement therapy products as Vivelle-Dot and CombiPatch, ADHD drug Daytrana (marketed by Shire), and a transmucosal lidocaine patch used for dental procedures. The company also produces and markets three psychiatric drugs. In 2009 Noven was acquired by Japanese drug-maker Hisamitsu Pharmaceutical for some $430 million.

Novavax, Inc. was founded in 1987 and is headquartered in Rockville, Maryland. Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products, and other diagnostic products for the territory of India. It also has a strategic collaboration Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine.

Hospira, Inc. company was founded in 2003 and is headquartered in Lake Forest, Illinois. Hospira, Inc., a specialty pharmaceutical and medication delivery company, engages in the development, manufacture, and marketing of pharmaceuticals and medication delivery systems in the United States and internationally. It offers generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems for hospitals, wholesalers, integrated delivery networks, and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company primarily provides specialty injectable pharmaceutical products that consist of generic injectable pharmaceuticals for analgesia, anesthesia, anti-infective, cardiovascular, and oncology therapeutic areas, as well as Precedex (dexmedetomidine HCl), a proprietary sedative. Its proprietary drug delivery options include Carpuject and iSecure prefilled syringes, Ansyr prefilled needleless emergency syringe systems, First Choice ready-to-use premixed formulations, and the ADD-Vantage System for preparing drug solutions from prepackaged drug powders or concentrates.Hospira, Inc. company also offers infusion therapy solutions and supplies that include I.V. solutions for general use; and I.V. nutrition products and solutions for the washing and cleansing of wounds or surgical sites. In addition, it provides medication management systems that include electronic drug delivery pumps, safety software, and administration sets that are used to deliver I.V. fluids and medications. Further, the company offers gravity administration sets, hemodynamic monitoring systems used to monitor cardiac function and blood flow in critically ill patients, disposable blood-pressure-sensing devices, blood sampling systems, catheter systems, and needle stick safety products. Additionally, Hospira involves in the provision of formulation development, and injectable and oral drug filling and finishing services.

Bayhill Therapeutics knows that some immune responses are just way out of line. The biopharmaceutical developer is designing vaccines to eliminate problematic immune responses and restore the immune system to its normal state, known as "tolerance." Its product candidate BHT-3009 is being studied in clinical trials as a treatment for multiple sclerosis while its other leading candidate BHT-3021 is in clinical trials for the treatment of type 1 diabetes. The company's pre-clinical candidate, BHT-3034 is being developed as a treatment for myasthenia gravis, an autoimmune disease that causes interruption in the transmission of nerve impulses to muscles.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.